Assessing the blood pressure-lowering efficacy of antihypertensive medications: Which blood pressures should we use?

Journal of Clinical Hypertension

Volumn 11, Issue 3, 2009, Pages 155-158

  Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; REFERENCE STANDARDS; TREATMENT OUTCOME;

EID: 63349098744     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00087.x     Document Type: Note

References (10)

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
3. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594-599.
4. Myers MG, Lipicky RJ. Assessment of antihypertensive activity in the regulatory setting. Blood Press Monit 2001;6:309-312.
5. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) 2007. Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Draft ICH Consensus Principle: Principles for Clinical Evaluation of New Antihypertensive Drugs. (Signed as a Principle Document on 2 March 2000 by the ICH Steering Committee). http://www.fda.gov/cder/Guidance/3774dft.htm. Accessed October 23, 2007.
7. Sica DA. Hypertension treatment: How important is consistency of effect? Hypertension. 2007;50:287-288.
8. Hebert CJ, Shidham G, Hebert LA. Should the target for blood pressure control specify both a systolic and a diastolic component? Curr Hypertens Rep. 2005;7:360-362.
9. Almgren T, Persson B, Wilhelmsen L, et al. Stroke and coronary heart disease in treated hypertension: A prospective cohort study over three decades. J Intern Med. 2005;257:496-502.
10. Pool JA, Glazer R, Weinberger M, et al. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.